A protracted, postherpetic neuralgic ulcer treated with risperidone and intranasal butorphanol

Ingrasci, Giuseppe; Arbrouk, Michael; Haitz, Karyn; Kirsner, Robert S.; Yosipovitch, Gil

doi:10.1016/j.jdcr.2021.06.026

Cited by 3 publications

(2 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nalbuphine, a KOR agonist and MOR antagonist, can prevent intrathecal morphine-induced pruritus and be effective against pruritus in prurigo nodularis and uremia [237][238][239][240][241]. Butorphanol, another KOR agonist and MOR antagonist, has been reported to reduce chronic pruritus associated with various dermatological, internal, and neurological diseases [242][243][244][245][246][247] (Table 1).…”

Section: Opioidsmentioning

confidence: 99%

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Elieh‐Ali‐Komi

Maurer

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (CTCL), which include mycosis fungoides (MF) and Sézary syndrome (SS), are a group of lymphoproliferative disorders characterized by clonal accumulation of neoplastic T-lymphocytes in the skin. Severe pruritus, one of the most common and distressing symptoms in primary CTCL, can significantly impair emotional well-being, physical functioning, and interpersonal relationships, thus greatly reducing quality of life. Unfortunately, effectively managing pruritus remains challenging in CTCL patients as the underlying mechanisms are, as of yet, not fully understood. Previous studies investigating the mechanisms of itch in CTCL have identified several mediators and their corresponding antagonists used for treatment. However, a comprehensive overview of the mediators and receptors contributing to pruritus in primary CTCL is lacking in the current literature. Here, we summarize and review the mediators and receptors that may contribute to pruritus in primary CTCL to explore the mechanisms of CTCL pruritus and identify effective therapeutic targets using the PubMed and Web of Science databases. Studies were included if they described itch mediators and receptors in MF and SS. Overall, the available data suggest that proteases (mainly tryptase), and neuropeptides (particularly Substance P) may be of greatest interest. At the receptor level, cytokine receptors, MRGPRs, and TRP channels are most likely important. Future drug development efforts should concentrate on targeting these mediators and receptors for the treatment of CTCL pruritus.

show abstract

Section: Opioidsmentioning

confidence: 99%

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Elieh‐Ali‐Komi

Maurer

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Eine erfolgreiche Behandlung des Pruritus wurde bei einem Patienten mit amyotropher Lateralsklerose durch Cannabinoide [ 79 ] beschrieben. Eine Besserung des Juckens und des Kratzverhaltens ist bei einer Patientin mit postherpetischem Pruritus durch die intranasale Gabe von Butorphanol und Risperidon [ 80 ] dokumentiert. Butorphanol ist ein Opioid, das als Agonist auf die κ‑ und δ‑Opioidrezeptoren und als Antagonist auf die μ‑Opioidrezeptoren wirkt [ 81 ], und Risperidon, ein Neuroleptikum, wurde erfolgreich zur Behandlung von Patienten mit einer wahnhaften Parasitose eingesetzt [ 82 , 83 ].…”

Section: Weitere Therapiemöglichkeitenunclassified

Neuropathischer Pruritus – evidenzbasierte Behandlungsempfehlungen

Baka

Birklein

2022

Nervenarzt

View full text Add to dashboard Cite

ZusammenfassungDer neuropathische Pruritus ist ein bisher vernachlässigtes Symptom einer Vielzahl von neurologischen Erkrankungen. Mechanische Engpasssyndrome peripherer Nerven oder Nervenwurzeln, raumfordernde Läsionen des Zentralnervensystems, chronisch-entzündliche neurologische Erkrankungen oder eine Polyneuropathie können einen neuropathischen Pruritus verursachen. Selbst wenn die Identifizierung der zugrunde liegenden neurologischen Erkrankung erfolgreich ist, ist eine kausale Therapie nicht immer möglich, sodass eine effiziente symptomatische Behandlung die einzige therapeutische Option darstellt. Der Zweck dieser Übersichtsarbeit ist, die aktuelle Literatur zu verschiedenen Wirkstoffen und Therapieoptionen bei der Behandlung des neuropathischen Pruritus darzustellen.

show abstract

Oxycodone

2021

Reactions Weekly

View full text Add to dashboard Cite

A protracted, postherpetic neuralgic ulcer treated with risperidone and intranasal butorphanol

Cited by 3 publications

References 10 publications

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Neuropathischer Pruritus – evidenzbasierte Behandlungsempfehlungen

Oxycodone

Contact Info

Product

Resources

About